Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May-Jun;11(4):381-389.
doi: 10.6004/jadpro.2020.11.4.5. Epub 2020 May 1.

Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management

Miriam Hobbs  1 , Amie Fonder  1 , Yi L Hwa  1
Affiliations

Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management

Miriam Hobbs et al. J Adv Pract Oncol. 2020 May-Jun.

Abstract

Waldenström macroglobulinemia is a rare hematologic malignancy characterized by an IgM-associated lymphoplasmacytic lymphoma. Often, it is associated with an indolent disease course, and many patients are candidates for careful monitoring. As many patients present with advanced age and nonspecific constitutional symptoms, careful consideration should be given to treatment decisions, including when and how to treat for maximized clinical benefit with minimal toxicity. This article provides an evidence-based practical approach to appropriate monitoring of the asymptomatic patient and management of symptomatic patients who require treatment for this rare malignancy.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Buske, C. (2018). Alkylating agents in the treatment of Waldenstrom Macroglobulinemia. Hematology/Oncology Clinics of North America, 32(5), 821–827. 10.1016/j.hoc.2018.05.009 - DOI - PubMed
    1. Castillo, J. J., Olszewski, A. J., Cronin, A. M., Hunter, Z. R., & Treon, S. P. (2014). Survival trends in Waldenstrom macroglobulinemia: An analysis of the Surveillance, Epidemiology and End Results database. Blood, 123(25), 3999–4000. 10.1182/blood-2014-05-574871 - DOI - PubMed
    1. Castillo, J. J., Olszewski, A. J., Kanan, S., Meid, K., Hunter, Z. R., & Treon, S. P. (2015). Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: An analysis of the Surveillance, Epidemiology and End Results database. British Journal of Haematology, 169(1), 81–89. 10.1111/bjh.13264 - DOI - PubMed
    1. Dhodapkar, M. V., Hoering, A., Gertz, M. A., Rivkin, S., Szymonifka, J., Crowley, J., & Barlogie, B. (2009). Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood, 113(4), 793–796. 10.1182/blood-2008-07-172080 - DOI - PMC - PubMed
    1. Dimopoulos, M. A., & Kastritis, E. (2019). How I treat Waldenstrom macroglobulinemia. Blood, 134(23), 2022–2035. 10.1182/blood.2019000725 - DOI - PubMed

LinkOut - more resources